Hadi Molanaei

Variations in C-reactive protein during a single haemodialysis session do not associate with mortality.

J. Carrero, F. Dekker, R. Krediet, 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation

J. Carrero, L. Bertilsson, P. Stenvinkel, 2012, European Journal of Clinical Pharmacology.

Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients

L. Bertilsson, P. Stenvinkel, B. Lindholm, 2018, BMC Pharmacology and Toxicology.

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability

J. Carrero, F. Dekker, R. Krediet, 2010 .

Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation

J. Carrero, L. Bertilsson, P. Stenvinkel, 2012, European Journal of Clinical Pharmacology.

Studies of drug disposition in hemodialysis patients : impact of genetics, inflammation and vitamin D

Hadi Molanaei, 2016 .

Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease

J. Carrero, L. Bertilsson, P. Stenvinkel, 2010, European Journal of Clinical Pharmacology.

Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients

L. Bertilsson, P. Stenvinkel, B. Lindholm, 2018, BMC Pharmacology and Toxicology.

MP666INFLAMMATION DOWN REGULATES CYTOCHROME P450 MEDINATED DRUG METABOLISM IN HEMODIALYSIS PATIENTS

L. Bertilsson, P. Stenvinkel, B. Lindholm, 2016 .